KRMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
KORU Medical Systems Inc (KRMD) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock shows some positive momentum in technical indicators and analyst ratings, the lack of significant recent news, weak financial performance, and absence of strong trading signals suggest it is better to hold off on investing right now.
The technical indicators show mixed signals. The MACD is positive but contracting, RSI is neutral at 36.481, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading below the pivot level of 4.796, with support at 4.544 and resistance at 5.048. This suggests limited upside potential in the short term.
Analysts have raised price targets recently, with Lake Street increasing the target to $8 and Canaccord to $6, both maintaining Buy ratings. The potential 510K submission for an oncology indication is a meaningful catalyst for future growth.
The company's financial performance in Q3 2025 showed declining net income (-50.79% YoY), EPS (-33.33% YoY), and gross margin (-3.88% YoY). Additionally, there is no recent news or significant insider or hedge fund activity to drive immediate interest.
In Q3 2025, revenue increased by 27.17% YoY to $10,402,163, but net income dropped significantly to -$777,966 (-50.79% YoY). EPS also declined to -0.02 (-33.33% YoY), and gross margin fell slightly to 58.26% (-3.88% YoY).
Analysts are optimistic about KRMD's future, with recent upgrades in price targets and Buy ratings. Lake Street raised the target to $8, citing growth acceleration and potential revenue upside, while Canaccord increased the target to $6, reflecting updated 2027 estimates.
